# Long-Acting Metabolic Implants Vivani and Novo Nordisk Evaluate a Long-Acting Semaglutide Implant By Mursal Rahman | Written with AI assistance | Published 2026-07-24 | Lifestyle Source: Trend Hunter, https://www.trendhunter.com/trends/Long-acting-metabolic-implants References: [cnbc](https://www.cnbc.com/2026/07/11/glp-1-implant-from-vivani-medical-aims-to-help-patients-stay-on-treatment.html) & [globenewswire](https://www.globenewswire.com/news-release/2026/07/07/3323068/0/en/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-miniature-ultra-long-acting-semaglutide-implant-for-chronic-weight-management.html)  Long-acting metabolic implants are advancing obesity treatment by replacing frequent injections with implantable therapies designed to provide medication over extended periods. Vivani Medical's NPM-139 uses the company's NanoPortal™ platform to steadily deliver semaglutide through a miniature implant that could require administration only once or twice a year. Novo Nordisk will evaluate the technology as Vivani prepares to begin a Phase 1 clinical study comparing the implant with Wegovy® injections for chronic weight management. For businesses, long-acting metabolic implants could address one of the biggest challenges in chronic disease treatment: medication adherence. Reducing the need for weekly injections may improve patient compliance while creating new opportunities for pharmaceutical companies to differentiate GLP-1 therapies in a rapidly expanding obesity market. Partnerships between drug developers and delivery technology companies also highlight growing demand for treatment platforms that improve convenience, support long-term outcomes, and broaden patient adoption of metabolic therapies. Image Credit: Vivani Medical ## Trend Insights (Trend Hunter) - Score: 6.2/10 - Popularity: 38% | Activity: 64% | Freshness: 84% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America, Europe, Asia ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Lifestyle](https://www.trendhunter.com/lifestyle) > [Health](https://www.trendhunter.com/health) ## Key Themes ### What's Driving This Trend - **Long-acting Drug Delivery:** Implantable platforms that release medication over months are reshaping chronic care by reducing dosing burdens and strengthening adherence in high-growth therapeutic categories. - **GLP-1 Treatment Differentiation:** As obesity therapies become more competitive, delivery innovations create new value around convenience, persistence, and patient preference beyond drug efficacy alone. - **Pharma-device Partnerships:** Collaborations between pharmaceutical companies and implant technology developers signal a broader shift toward integrated treatment systems that combine biologics expertise with advanced delivery hardware. ### Who This Affects Most - **Pharmaceuticals:** The obesity drug market is gaining fresh competitive pathways through sustained-release formulations that extend product lifecycles and improve treatment accessibility. - **Medical Devices:** Miniature implant systems are opening new commercial space for device makers focused on precision release, minimally invasive administration, and chronic disease management. - **Digital Health:** Long-duration therapies create adjacent opportunities for adherence monitoring, remote follow-up, and patient support platforms that help manage outcomes between clinical visits. ## Related on Trend Hunter - [Oral GLP-1 Supplements](https://www.trendhunter.com/trends/evolv-glp1.md) - [Metabolic Wellness Systems](https://www.trendhunter.com/trends/maeva.md) - [Revolutionary Life-Saving Medication Storage](https://www.trendhunter.com/trends/lifesaving-medication.md) - [Same-Day GLP-1 Services](https://www.trendhunter.com/trends/amazon-pharmacy-glp-1.md) - [Medically Tailored Meals](https://www.trendhunter.com/trends/nimbus-meals-by-snap-kitchen.md) - [Oral GLP-1 Medicines](https://www.trendhunter.com/trends/wegovy-pill.md) - [Weight-Management Program Expansions](https://www.trendhunter.com/trends/suite-of-wellness-solutions.md) - [GLP-1 Medication-Offering Health Platforms](https://www.trendhunter.com/trends/futurhealth.md) - [Oral GLP-1 Commercials](https://www.trendhunter.com/trends/novo-nordisk-super-bowl.md)